Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.

Novo Nordisk announced that the European Medicines Agency (EMA) has approved an update to the label for Rybelsus (oral ...

Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals' portfolio of Factor XIa inhibitors to expand its anticoagulation ...

The deal marks the second time Novartis has tapped Monte Rosa’s services in just under year. The US big pharma company paid ...